<table>
<thead>
<tr>
<th>Tumor Class</th>
<th>428 classifier Training set</th>
<th>428 classifier Test set</th>
<th>641 classifier Combined set</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Samples (n)</td>
<td>Correct (%)</td>
<td>Samples (n)</td>
</tr>
<tr>
<td>Bladder</td>
<td>40</td>
<td>77.5</td>
<td>5</td>
</tr>
<tr>
<td>Breast</td>
<td>260</td>
<td>95.8</td>
<td>52</td>
</tr>
<tr>
<td>Cervix</td>
<td>21</td>
<td>71.4</td>
<td>15</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>5</td>
<td>40.0</td>
<td>4</td>
</tr>
<tr>
<td>Colon/rectum</td>
<td>275</td>
<td>96.0</td>
<td>96</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>6</td>
<td>66.7</td>
<td>5</td>
</tr>
<tr>
<td>Kidney</td>
<td>191</td>
<td>97.4</td>
<td>62</td>
</tr>
<tr>
<td>Lung</td>
<td>95</td>
<td>90.5</td>
<td>64</td>
</tr>
<tr>
<td>Malignant melanoma</td>
<td>13</td>
<td>76.9</td>
<td>46</td>
</tr>
<tr>
<td>Ovary</td>
<td>121</td>
<td>90.1</td>
<td>183</td>
</tr>
<tr>
<td>Pancreas</td>
<td>19</td>
<td>78.9</td>
<td>39</td>
</tr>
<tr>
<td>Prostate</td>
<td>60</td>
<td>98.3</td>
<td>18</td>
</tr>
<tr>
<td>Stomach/cardia</td>
<td>18</td>
<td>72.2</td>
<td>21</td>
</tr>
<tr>
<td>Testis</td>
<td>6</td>
<td>100.0</td>
<td>5</td>
</tr>
<tr>
<td>Thyroid</td>
<td>47</td>
<td>87.2</td>
<td>14</td>
</tr>
<tr>
<td>Uterus</td>
<td>122</td>
<td>90.2</td>
<td>12</td>
</tr>
<tr>
<td>Normal</td>
<td>167</td>
<td>90.4</td>
<td>101</td>
</tr>
<tr>
<td>Overall</td>
<td>1466</td>
<td>92.2</td>
<td>641</td>
</tr>
<tr>
<td>Primary tumours</td>
<td>1299</td>
<td>92.4</td>
<td>391</td>
</tr>
<tr>
<td>Metastases</td>
<td>-</td>
<td>-</td>
<td>250</td>
</tr>
<tr>
<td>Normal tissue</td>
<td>167</td>
<td>90.4</td>
<td>101</td>
</tr>
</tbody>
</table>

Table S2. Prediction of tumor classes with the 428 and 641 classifiers.